Episode 45: A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies

Posted August 3, 2021

Wendy Vogel, MSN, FNP, AOCNP®

Donald C. Moore, PharmD, BCPS, BCOP, DPLA

Donald C. Moore, PharmD, BCPS, BCOP, DPLA, of Atrium Health, Levine Cancer Institute, in Concord, North Carolina, talks with host Wendy Vogel, MSN, FNP, AOCNP®, on recent data and strategies for managing adverse events of ibrutinib, acalabrutinib, and zanubrutinib in the treatment of B-cell malignancies.

Related Content:

A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies. J Adv Pract Oncol 2021;12(4):439–447. https://doi.org/10.6004/jadpro.2021.12.4.8